Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
- PMID: 22378068
- PMCID: PMC3317343
- DOI: 10.1038/cddis.2012.13
Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) acts as a major sensor of cellular energy status in cancers and is critically involved in cell sensitivity to anticancer agents. Here, we showed that AMPK was inactivated in lymphoma and related to the upregulation of the mammalian target of rapamycin (mTOR) pathway. AMPK activator metformin potentially inhibited the growth of B- and T-lymphoma cells. Strong antitumor effect was also observed on primary lymphoma cells while sparing normal hematopoiesis ex vivo. Metformin-induced AMPK activation was associated with the inhibition of the mTOR signaling without involving AKT. Moreover, lymphoma cell response to the chemotherapeutic agent doxorubicin and mTOR inhibitor temsirolimus was significantly enhanced when co-treated with metformin. Pharmacologic and molecular knock-down of AMPK attenuated metformin-mediated lymphoma cell growth inhibition and drug sensitization. In vivo, metformin induced AMPK activation, mTOR inhibition and remarkably blocked tumor growth in murine lymphoma xenografts. Of note, metformin was equally effective when given orally. Combined treatment of oral metformin with doxorubicin or temsirolimus triggered lymphoma cell autophagy and functioned more efficiently than either agent alone. Taken together, these data provided first evidence for the growth-inhibitory and drug-sensitizing effect of metformin on lymphoma. Selectively targeting mTOR pathway through AMPK activation may thus represent a promising new strategy to improve treatment of lymphoma patients.
Figures
Similar articles
-
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.J Hematol Oncol. 2013 Jul 18;6:53. doi: 10.1186/1756-8722-6-53. J Hematol Oncol. 2013. PMID: 23866964 Free PMC article.
-
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.Anticancer Res. 2012 May;32(5):1627-37. Anticancer Res. 2012. PMID: 22593441
-
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4. Clin Cancer Res. 2011. PMID: 21543517
-
Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways.Cell Biochem Funct. 2024 Jun;42(4):e4071. doi: 10.1002/cbf.4071. Cell Biochem Funct. 2024. PMID: 38863255 Review.
-
Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?Curr Drug Targets. 2017;18(6):734-750. doi: 10.2174/1389450118666161205125548. Curr Drug Targets. 2017. PMID: 27919208 Review.
Cited by
-
Ianus Bifrons: The Two Faces of Metformin.Cancers (Basel). 2024 Mar 26;16(7):1287. doi: 10.3390/cancers16071287. Cancers (Basel). 2024. PMID: 38610965 Free PMC article. Review.
-
Autophagy Modulation and Its Implications on Glioblastoma Treatment.Curr Issues Mol Biol. 2023 Oct 29;45(11):8687-8703. doi: 10.3390/cimb45110546. Curr Issues Mol Biol. 2023. PMID: 37998723 Free PMC article. Review.
-
Dissecting the Role of Autophagy-Related Proteins in Cancer Metabolism and Plasticity.Cells. 2023 Oct 19;12(20):2486. doi: 10.3390/cells12202486. Cells. 2023. PMID: 37887330 Free PMC article. Review.
-
Old drug, new tricks: the utility of metformin in infection and vaccination responses to influenza and SARS-CoV-2 in older adults.Front Aging. 2023 Oct 11;4:1272336. doi: 10.3389/fragi.2023.1272336. eCollection 2023. Front Aging. 2023. PMID: 37886013 Free PMC article. Review.
-
Cogs in the autophagic machine-equipped to combat dementia-prone neurodegenerative diseases.Front Mol Neurosci. 2023 Aug 31;16:1225227. doi: 10.3389/fnmol.2023.1225227. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37720551 Free PMC article. Review.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 60;5:277–300. - PubMed
-
- Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95. - PubMed
-
- Cao Y, Li H, Liu H, Zheng C, Ji H, Liu X. The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression. Cell Res. 2010;20:99–108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous